Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
IVERMECTIN
The George Institute
Strongyloidiasis is caused by a parasite that is globally distributed in tropical and sub-tropical areas. Most patients with strongyloidiasis are asymptomatic or have mild symptoms with gastrointestinal disturbances, respiratory symptoms, and skin lesions. In situations of low defenses (patients under treatment with corticosteroids, organ transplant recipients or other situations) they can present serious complications with high mortality.
1 trial -
JNJ-73841937, JNJ-61186372, Zirabev 25 mg/ml concentrate for solution for infusion.
Partner Therapeutics Limited
Patients with EGFR-mutant (L858R or del19 only) advanced non-squamous NSCLC, who have progressed on previous treatment with a third-generation EGFR-TKI.
1 trial -
KALINOX 50%/50%, gaz medicinal comprime, Medical Air
Tour Hekla
Treatment of suicidal ideation
1 trial -
KT-621, KT-621, KT-621, The placebo is used in the Double-blind, Placebo-controlled (DBPC) Treatment Period. Participants are randomly assigned to receive either KT-621 or a matching placebo. The placebo is designed to match the study drug in appearance and administration method to maintain blinding.
Kymera Therapeutics
Moderate to Severe Atopic Dermatitis
1 trial -
Lenvatinib, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Fondazione Telethon ETS
Advanced unresectable classic Kaposi sarcoma relapsed and/or refractory to previous standard treatments.
1 trial -
Lenvatinib, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-4830, ETOPOSIDE, Lenvatinib, CISPLATIN, boserolimab, CARBOPLATIN
Merck Sharp and Dohme
First-line treatment of participants with extensive-stage small cell lung cancer
1 trial -
Liraglutide Pen Injector
BRIGHT MINDS BIOSCIENCES INC.
Opiate Substitution Treatment
1 trial -
Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction treatment for patients aged 18 to 60 (up to 65 for phase II) with a newly diagnosed Primary Central Nervous System Lymphoma
The George Institute
Primary Central Nervous System Lymphoma (PCNSL)
1 trial -
Mebufotenin, Mebufotenin, Inhalation vapour, liquid, Mebufotenin
Elan Pharma International
Treatment-resistant depression (TRD)
1 trial -
Mektovi 15 mg film-coated tablets, Tyverb 250 mg film-coated tablets, Vinorelbine Accord 10 mg/ml concentraat voor oplossing voor infusie
Disc Medicine
metastatic colorectal cancer with a proven RAS mutation after failure of standard systemic treatment regimens including at least 5- FU/capecitabine-oxaliplatin and irinotecan based standard treatment (unless contra-indications for either oxaliplatin or irinotecan)
1 trial -
Metronidazole 500 mg / 100 ml Intravenous Infusion, Metronidazole 500mg/100ml Solution for Infusion, Aztreonam and Avibactam (1.5g/0.5g) Powder for Concentrate for Solution for Infusion, Metronidazole
Pfizer Australia Pty Ltd
Sepsis, Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment, Complicated Urinary Tract Infection, Blood Stream Infection, Hospital-acquired pneumonia or ventilator-associated pneumonia, Complicated Intra-abdominal Infection
1 trial -
Mifepristone 1200 mg daily
CORCEPT THERAPEUTICS INC
Treatment-resistant PTSD
1 trial -
NS-229 matching tablets with no active treatment, NS-229
Lacuna Pharma Pty Ltd
Eosinophilic granulomatosis with polyangiitis (EGPA)
1 trial -
NV-5138
SUPERNUS PHARMACEUTICALS, INC.
Treatment Resistant Depression
1 trial -
Nilotinib followed by treatment-free
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia
1 trial -
ORMD-0801 Treatment A
ORAMED PHARMACEUTICALS INC.
Type 1 Diabetes
1 trial -
OXALIPLATIN, PANITUMUMAB, Lonsurf 15 mg/6.14 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, BEVACIZUMAB, NIVOLUMAB, TRASTUZUMAB
Ningbo Cancer Hospital
Patients with pMMR/MSS metastatic adenocarcinoma of the colon or rectum or gastroesophageal cancer (lower esophagus, gastroesophageal junction and gastric) and with known dihydropyrimidine dehydrogenase (DPD) deficiency defined as plasma uracil concentration ≥16 ng/ml, who undergo first-line treatment
1 trial -
Open-label, safety, tolerability and proof of concept study to evaluate the use of ANXV (recombinant human Annexin A5 protein) in the treatment of patients with either Diabetic Retinopathy or recent onset Retinal Vein Occlusion
Lacuna Pharma Pty Ltd
Diabetic Retinopathy, Retinal Vein Occlusion
1 trial -
Organoid-guided treatment
The First People's Hospital of Lianyungang
HER2-negative Breast Cancer
1 trial -
PCN-101
Chongqing Precision Biotech Co., Ltd
Treatment Resistant Depression
1 trial -
Phase 1b/2 trial of 5-fluorouracil, leucovorin, irinotecan in combination with temozolomide (FLIRT) and bevacizumab for the first-line treatment of patients with MGMT silenced, microsatellite stable metastatic colorectal cancer.
Fondazione Telethon ETS
metastatic colorectal cancer
1 trial -
Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3-DXd monotherapy and combinations in Patients with inoperable advanced breast cancer (ABC) after progression on T-DXd- (ICARUS BREAST 2)
The George Institute
Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-low defined as a score 1+ on immunohistochemistry [IHC] or as an IHC score 2+ and negative results on in situ hybridization (ISH) (cohort 2) ABC, and any hormone receptor (HR) status, who have progressed on trastuzumab deruxtecan (T-DXd). In addition to previous T-DXd, patients with HER2-pos tumors must have received prior treatment with trastuzumab (+/- pertuzumab) and taxanes and may have received T-DM1. Patients with HER2-low tumors must have received prior treatment with taxanes. Patients with HR-positive (HR+) and HER2-low tumor must have received prior treatment with endocrine therapy and CDK4/6 inhibitors.
1 trial -
Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma
The George Institute
Malignant Peritoneal Mesothelioma
1 trial -
Pimavanserin
Acadia Pharmaceuticals B.V.
Treatment of Depression in Adults With Parkinson's Disease (PD)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources